CRISPR TherapeuticsCRSP
About: Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Employees: 393
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
50% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 6 (+2) [Q1 2025]
27% more call options, than puts
Call options by funds: $96.3M | Put options by funds: $75.6M
17% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 102
0.82% less ownership
Funds ownership: 75.6% [Q4 2024] → 74.78% (-0.82%) [Q1 2025]
4% less funds holding
Funds holding: 397 [Q4 2024] → 383 (-14) [Q1 2025]
14% less first-time investments, than exits
New positions opened: 51 | Existing positions closed: 59
14% less capital invested
Capital invested by funds: $2.54B [Q4 2024] → $2.19B (-$356M) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
JMP Securities Silvan Tuerkcan | 108%upside $86 | Market Outperform Reiterated | 21 May 2025 |
Needham Gil Blum | 96%upside $81 | Buy Reiterated | 20 May 2025 |
HC Wainwright & Co. Mitchell Kapoor | 57%upside $65 | Buy Reiterated | 20 May 2025 |
Barclays Gena Wang | 2%upside $42 | Equal-Weight Maintained | 9 May 2025 |
Goldman Sachs Salveen Richter | 14%upside $47 | Neutral Maintained | 8 May 2025 |
Financial journalist opinion
Based on 18 articles about CRSP published over the past 30 days
